LLY News and Press, Eli Lilly and Company From 04/09/24

2024-04-09 12:37:13 ET More on Structure Therapeutics Seeking Alpha’s Quant Rating on Structure Therapeutics Historical earnings data for Structure Therapeutics Financial information for Structure Therapeutics Read the full article on Seeking Alpha ...

2024-04-09 11:30:10 ET Summary Today, we take a look at Novo Nordisk A/S, whose growth is being powered by Wegovy and Ozempic. The GLP-1 market is projected by some to grow to $100 billion by 2030 and Novo Nordisk is currently the preeminent player in this burgeoning space. Ho...

2024-04-09 10:03:48 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...

2024-04-09 05:49:33 ET Summary After nearly a decade of struggles, Perrigo is poised to turn the corner under the leadership of a new CEO who is only nine months in the seat. Infant formula woes will be resolved in Q2 and comparisons year over year will start to be favorable in th...

2024-04-08 15:11:44 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tic...

2024-04-08 08:30:00 ET Earnings season, which is fast approaching, is often somewhat volatile for the stock market. Companies that overdeliver or fail to deliver can see their share prices move significantly overnight. However, long-term investors know that one quarterly report rarely c...

2024-04-08 06:30:00 ET Eli Lilly 's (NYSE: LLY) shares have soared over the past year as the company grew its presence in what could become a $100 billion drug market. The company sells two drugs prescribed for weight loss -- Mounjaro and Zepbound -- and they're likely to become lon...

2024-04-07 11:09:34 ET More on the markets SPY: The Correction May Be Massive S&P 500: International Risk Assessment My Current View Of The Market: April 2024 Edition (Technical Analysis) S&P 500 sees worst week of 2024 as strong labor market data den...

2024-04-07 07:15:00 ET As two of the most-watched and fastest-growing big pharma companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) already have upwardly mobile stock prices. And now, there's yet another piece of news that could presage even more growth over t...

2024-04-06 08:30:00 ET The battle for leadership in the anti-obesity drug market is heating up. Eli Lilly (NYSE: LLY) and Novo Nordisk are the two undisputed frontrunners, but many other drugmakers are looking to challenge the status quo. Novo Nordisk's Wegovy, first approved in...